Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
Table 3
Logistic regression and propensity score-based analyses to predict treatment response with tocilizumab versus TNFi.
Remission
Low disease activity
Odds ratio
95% CI
value
Odds ratio
95% CI
value
DAS28 < 2.6
DAS28 < 3.2
Multivariate LR
489
13.3
6.9–25.4
<0.001
7.3
3.9–13.6
<0.001
Univariate LR + PS
489
8.3
4.4–15.4
<0.001
5.5
2.9–10.5
<0.001
Multivariate LR + PS
489
11.0
5.6–21.6
<0.001
6.2
3.2–12.0
<0.001
PS matching
259
7.9
4.3–14.6
<0.001
5.0
2.7–9.2
<0.001
PS matching + multivariate LR
259
12.3
6.0–25.4
<0.001
7.5
3.7–15.1
<0.001
CDAI ≤ 2.8
CDAI ≤ 10
Multivariate LR
308
2.9
1.3–6.6
0.009
3.0
1.5–6.1
0.002
Univariate LR + PS
308
2.5
1.1–5.6
0.022
2.3
1.1–4.6
0.019
Multivariate LR + PS
308
2.8
1.2–6.5
0.016
2.6
1.3–5.5
0.010
PS matching
179
2.1
0.92–5.0
0.078
2.0
1.00–4.1
0.048
PS matching + multivariate LR
179
3.3
1.3–8.4
0.015
2.6
1.2–5.6
0.017
SDAI ≤ 3.3
SDAI ≤ 11
Multivariate LR
282
4.1
1.7–9.5
0.001
2.9
1.4–6.3
0.005
Univariate LR + PS
282
3.1
1.3–7.0
0.008
2.2
1.04–4.8
0.038
Multivariate LR + PS
282
3.6
1.5–8.7
0.005
2.5
1.1–5.5
0.024
PS matching
158
2.6
1.1–6.4
0.029
1.6
0.8–3.5
0.209
PS matching + multivariate LR
158
4.0
1.5–10.8
0.007
2.2
0.95–5.0
0.065
Boolean
Multivariate LR
442
2.1
0.91–4.8
0.083
Univariate LR + PS
442
1.8
0.76–4.0
0.184
Multivariate LR + PS
442
1.9
0.77–4.8
0.159
PS matching
216
1.2
0.54–2.9
0.629
PS matching + multivariate LR
216
1.4
0.54–3.9
0.463
Good EULAR
Good/moderate EULAR
Multivariate LR
489
6.8
3.8–12.3
<0.001
2.5
1.1–5.9
0.035
Univariate LR + PS
489
6.3
3.4–11.8
<0.001
1.8
0.8–4.1
0.143
Multivariate LR + PS
489
6.4
3.4–12.0
<0.001
1.8
0.8–4.5
0.182
PS matching
259
6.2
3.3–11.6
<0.001
2.2
0.93–5.2
0.074
PS matching + multivariate LR
259
7.8
4.0–15.4
<0.001
2.4
0.98–6.1
0.056
The odds ratio and 95% confidence interval (95% CI) for the effect of tocilizumab versus TNF inhibitors (TNFi) in the considered outcomes are represented according to the statistical methodology used. Multivariate logistic regression (LR) adjusted for other significant confounders as described in Section 2, namely, age, disease duration, number of previous biologics, and baseline disease activity (DAS28 for DAS28/Boolean remission, DAS28 low disease activity (LDA), and EULAR response; CDAI for CDAI remission/LDA; SDAI for SDAI remission/LDA). Propensity scores (PS) predicting biologic class were calculated and incorporated in the analysis, via LR and/or matching (caliper 1 : 5 with replacement). value significant at <0.05; significant differences highlighted in bold.
